Cargando…

Late cardiopulmonary toxicity after treatment for Hodgkin's disease.

Cardiac and pulmonary functions were evaluated in 75 patients aged 50 years or under, treated for Hodgkin's disease by mantle radiotherapy at least 3 years earlier; all received the same mantle field radiotherapy: radiotherapy alone, MOPP chemotherapy plus radiotherapy, MOPP and ABVD chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Allavena, C., Conroy, T., Aletti, P., Bey, P., Lederlin, P.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977758/
https://www.ncbi.nlm.nih.gov/pubmed/1616862
_version_ 1782135330801975296
author Allavena, C.
Conroy, T.
Aletti, P.
Bey, P.
Lederlin, P.
author_facet Allavena, C.
Conroy, T.
Aletti, P.
Bey, P.
Lederlin, P.
author_sort Allavena, C.
collection PubMed
description Cardiac and pulmonary functions were evaluated in 75 patients aged 50 years or under, treated for Hodgkin's disease by mantle radiotherapy at least 3 years earlier; all received the same mantle field radiotherapy: radiotherapy alone, MOPP chemotherapy plus radiotherapy, MOPP and ABVD chemotherapy plus radiotherapy. No patient had any symptom of heart disease. Only borderline abnormalities of ECG or echocardiogram were observed in 12 patients. One of them showed a moderate aortic stenosis which was known before the treatment; apical or septum hypokinesia were present in four patients and one patient had a slightly right ventricular dilatation. Twelve (16%) chest radiographs showed moderate or severe abnormalities, but there was no significant correlation between the results of pulmonary function tests and Xenon ventilation/perfusion scintigraphy, the clinical examination and the intensity of the radiological sequelae. Twenty-nine (64%) Xenon scintigraphies showed a reduction of lung perfusion in the irradiated areas without any symptom. The resting mean pulmonary function test was significantly lower for the patients than for the control group with regard to Total Capacity and Vital Capacity. The exercise tolerance, as indicated by analysis of blood gases, was below the one expected for only two patients who were dyspneic during the low level of exercise. We did not find any significant difference between the three treatment groups. We conclude that the treatment with mantle field under good technical conditions (high energy photons, moderate doses...) can result in minimal cardiopulmonary dysfunction.
format Text
id pubmed-1977758
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19777582009-09-10 Late cardiopulmonary toxicity after treatment for Hodgkin's disease. Allavena, C. Conroy, T. Aletti, P. Bey, P. Lederlin, P. Br J Cancer Research Article Cardiac and pulmonary functions were evaluated in 75 patients aged 50 years or under, treated for Hodgkin's disease by mantle radiotherapy at least 3 years earlier; all received the same mantle field radiotherapy: radiotherapy alone, MOPP chemotherapy plus radiotherapy, MOPP and ABVD chemotherapy plus radiotherapy. No patient had any symptom of heart disease. Only borderline abnormalities of ECG or echocardiogram were observed in 12 patients. One of them showed a moderate aortic stenosis which was known before the treatment; apical or septum hypokinesia were present in four patients and one patient had a slightly right ventricular dilatation. Twelve (16%) chest radiographs showed moderate or severe abnormalities, but there was no significant correlation between the results of pulmonary function tests and Xenon ventilation/perfusion scintigraphy, the clinical examination and the intensity of the radiological sequelae. Twenty-nine (64%) Xenon scintigraphies showed a reduction of lung perfusion in the irradiated areas without any symptom. The resting mean pulmonary function test was significantly lower for the patients than for the control group with regard to Total Capacity and Vital Capacity. The exercise tolerance, as indicated by analysis of blood gases, was below the one expected for only two patients who were dyspneic during the low level of exercise. We did not find any significant difference between the three treatment groups. We conclude that the treatment with mantle field under good technical conditions (high energy photons, moderate doses...) can result in minimal cardiopulmonary dysfunction. Nature Publishing Group 1992-06 /pmc/articles/PMC1977758/ /pubmed/1616862 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Allavena, C.
Conroy, T.
Aletti, P.
Bey, P.
Lederlin, P.
Late cardiopulmonary toxicity after treatment for Hodgkin's disease.
title Late cardiopulmonary toxicity after treatment for Hodgkin's disease.
title_full Late cardiopulmonary toxicity after treatment for Hodgkin's disease.
title_fullStr Late cardiopulmonary toxicity after treatment for Hodgkin's disease.
title_full_unstemmed Late cardiopulmonary toxicity after treatment for Hodgkin's disease.
title_short Late cardiopulmonary toxicity after treatment for Hodgkin's disease.
title_sort late cardiopulmonary toxicity after treatment for hodgkin's disease.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977758/
https://www.ncbi.nlm.nih.gov/pubmed/1616862
work_keys_str_mv AT allavenac latecardiopulmonarytoxicityaftertreatmentforhodgkinsdisease
AT conroyt latecardiopulmonarytoxicityaftertreatmentforhodgkinsdisease
AT alettip latecardiopulmonarytoxicityaftertreatmentforhodgkinsdisease
AT beyp latecardiopulmonarytoxicityaftertreatmentforhodgkinsdisease
AT lederlinp latecardiopulmonarytoxicityaftertreatmentforhodgkinsdisease